Gabelli Funds LLC Acquires 11,200 Shares of Pfizer Inc. $PFE

Key Points

• Gabelli Funds LLC has increased its stake in Pfizer Inc. by 1.1%, acquiring an additional 11,200 shares, bringing its total holdings to 1,040,925 shares worth approximately $26.38 million.
• Several analysts have recently adjusted their price targets for Pfizer, with UBS and Goldman Sachs increasing their targets to $25.00 and $27.00, respectively, and the consensus rating for the company is currently a "Hold."
• Pfizer reported quarterly earnings of $0.78 per share, exceeding expectations, with a revenue of $14.65 billion and a declared quarterly dividend of $0.43, reflecting a robust annual yield of 6.9%.

Gabelli Funds LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,040,925 shares of the biopharmaceutical company's stock after acquiring an additional 11,200 shares during the period. Gabelli Funds LLC's holdings in Pfizer were worth $26,377,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter valued at $27,000. North Capital Inc. bought a new position in shares of Pfizer in the first quarter valued at $28,000. Finally, Bayforest Capital Ltd bought a new position in shares of Pfizer in the first quarter valued at $28,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on PFE. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Wolfe Research increased their price target on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group increased their price target on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Finally, Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

PFE opened at $24.97 on Wednesday. The business has a fifty day simple moving average of $24.74 and a 200 day simple moving average of $24.39. The company has a market capitalization of $141.94 billion, a PE ratio of 13.28, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer's payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.